Verdict: $140 Million in Illinois against AbbVie for testosterone heart attack
October 5th, 2017: A federal jury in Illinois found AbbVie Inc. liable for failing to warn of the risks of heart attacks from it’s popular AndroGel testosterone replacement products. Plaintiff Jeffrey Konrad was awarded $140,000.00 in damages for his injuries and the jury awarded an additional 1,000 times in punitive damages. The punitive damages equal $140 million.
AbbVie, the maker of AndroGel, was found to be negligent, misrepresented the harm of AndroGel by concealment, and intentionally misrepresented the risks of their product. AbbVie faces thousands of cases across the country for it’s failure to warn about the risks of AndroGel. Levin Simes represents plaintiffs who suffered a heart attack or stroke after starting testosterone replacement therapy.
This is the second bellwether case to reach a verdict. While the first jury found that AndroGel did not cause the first plaintiff’s heart attack, the jury also found that AbbVie misrepresented their product and awarded $150 million in punitive damages.
You can read more at our AndroGel page, or our TRT testosterone-replacement-therapy page. See also our blog post on whether or not these companies hid the heart attack and stroke risks of their testosterone gel, patch, and injection products.
- TRT Testosterone Replacement Therapy – Heart Attacks & Strokes
- Did sponsored studies hide risks of testosterone?